Narrow search
Showing 1 - 10 of 252
Cover Image
Valuing Health at Different Ages: Evidence from a Nationally Representative Survey in the US
Eisenberg, Daniel; Freed, Gary L.; Davis, Matthew M.; … - In: Applied Health Economics and Health Policy 9 (2011) 3, pp. 149-156
and analyse nationally representative data in the US regarding how people prioritize health programmes for children versus …. Participants were asked for their preferences between health programmes benefiting 100 children aged 10 years versus health … choices. Results: The survey response rate was 64% (n - 2132). Most respondents favoured programmes for 100 children aged 10 …
Persistent link: https://www.econbiz.de/10010614265
Cover Image
Patent Extension Policy for Paediatric Indications: An Evaluation of the Impact within Three Drug Classes in a State Medicaid Programme
Nelson, Richard E.; McAdam-Marx, Carrie; Evans, Megan L.; … - In: Applied Health Economics and Health Policy 9 (2011) 3, pp. 171-181
Background: The Food and Drug Administration Modernization Act (FDAMA) of 1997, Best Pharmaceuticals for Children Act … exclusivity extensions for conducting studies of their medications in children. The costs found in this study are just a small …
Persistent link: https://www.econbiz.de/10010614273
Cover Image
Assessing the Performance of a New Generic Measure of Health-Related Quality of Life for Children and Refining it for Use in Health State Valuation
Stevens, Katherine - In: Applied Health Economics and Health Policy 9 (2011) 3, pp. 157-169
scales were developed from interviews with children. Some of these dimensions have alternative wording choices. The measure … valuation to make it suitable for use in economic evaluation. Methods: A sample of 247 children was recruited from general and … clinical samples and according to the level of health of children. 96% of the school sample and 85% of the clinical sample were …
Persistent link: https://www.econbiz.de/10010614279
Cover Image
Hospital Costs, Length of Stay and Mortality Associated with Childhood, Adolescent and Young Adult Meningococcal Disease in the US
Davis, Keith L.; Bell, Timothy J.; Miller, Jacqueline M.; … - In: Applied Health Economics and Health Policy 9 (2011) 3, pp. 197-207
IMD among children, adolescents and young adults in the US. Methods: The study design was a retrospective analysis of …) controls. Results: A weighted total of 735 IMD admissions were identified. Among children, adjusted mean LOS and cost per …
Persistent link: https://www.econbiz.de/10010614287
Cover Image
Burden and Cost of Hospital Admissions for Vaccine-Preventable Paediatric Pneumococcal Disease and Non-Typable Haemophilus influenzae Otitis Media in New Zealand
Milne, Richard J.; Vander Hoorn, Stephen - In: Applied Health Economics and Health Policy 8 (2010) 5, pp. 281-300
children aged <20 years with pneumococcal meningitis or bacteraemia, pneumonia or otitis media were identified in national …, bacteraemia and pneumonia, respectively, for children aged <2 years; 8.4, 14.9 and 295 for children aged <5 years (including those … aged <2 years); and 2.2, 4.4 and 97 for children aged <20 years (including those aged <5 years). Mean rates per 100 000 in …
Persistent link: https://www.econbiz.de/10008506285
Cover Image
Methodological Challenges Posed by Economic Evaluations of Early Childhood Intervention Programmes
Petrou, Stavros; Gray, Ron - In: Applied Health Economics and Health Policy 4 (2005) 3, pp. 175-181
-emotional functioning and physical health of preschool children and enhancing their emerging competencies. This article presents a …
Persistent link: https://www.econbiz.de/10005448950
Cover Image
Can We Use Contingent Valuation to Assess the Demand for Childhood Immunisation in Developing Countries?: A Systematic Review of the Literature
Yeung, Raymond Y.T.; Smith, Richard D. - In: Applied Health Economics and Health Policy 4 (2005) 3, pp. 165-173
Childhood immunisation is one of the most cost-effective public health interventions, yet its population coverage in low- and middle-income countries is severely limited by the fiscal constraints that health services face. A recent proposal suggested that commitments to purchase vaccines and...
Persistent link: https://www.econbiz.de/10005590261
Cover Image
Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comp...
Haim Erder, M.; Xie, Jipan; Signorovitch, James E.; … - In: Applied Health Economics and Health Policy 10 (2012) 6, pp. 381-395
Background:Background: About 7% of children and adolescents are diagnosed with attention-deficit/hyperactivity disorder … the US Food and Drug Administration for once-daily use in the treatment of children and adolescents with ADHD in the US … assess the cost effectiveness of GXR versus ATX for the treatment of ADHD in children and adolescents, using the comparative …
Persistent link: https://www.econbiz.de/10010585886
Cover Image
Five-Year Evolution of Drug Prescribing in a University Adult Intensive Care Unit
Carron, Christine; Voirol, Pierre; Eggimann, Philippe; … - In: Applied Health Economics and Health Policy 10 (2012) 5, pp. 355-358
Persistent link: https://www.econbiz.de/10011005058
Cover Image
PleurX Peritoneal Catheter Drainage System for Vacuum-Assisted Drainage of Treatment-Resistant, Recurrent Malignant Ascites: A NICE Medical Technology Guidance
White, Judith; Carolan-Rees, Grace - In: Applied Health Economics and Health Policy 10 (2012) 5, pp. 299-308
The PleurX peritoneal drainage catheter for drainage of malignant ascites in a community setting has been evaluated by the NICE Medical Technologies Evaluation Programme. This article outlines the evidence included in the Sponsor's submission, the independent critique by the External Assessment...
Persistent link: https://www.econbiz.de/10011005059